Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer
Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer
Recruiting · NCT06962137 · Registry updated 2025-12-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma; Gastric Cancer Adenocarcinoma Metastatic | Recruiting | Phase 2 | 2025-12-22 | NCT06962137 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Universitaire Ziekenhuizen KU Leuven | 262 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| AZ Delta Roeselare | Roeselare | Belgium | 4 |
| Cliniques Universitaires Saint-Luc Brussels | Brussels | Belgium | 2 |
| HUB | Brussels | Belgium | 1 |
| UZ Gent | Ghent | Belgium | 26 |
| UZ Leuven | Leuven | Belgium | 236 |
| UZA | Antwerp | Belgium | 9 |